Context Therapeutics Buys Full CT-202 Rights for $6.5M, Eyes Q3 2026 Trial
CNTX•Context Therapeutics will pay $4.5 million upfront and $2.0 million by August 2026 to acquire full economic rights to CT-202, eliminating all future milestone and royalty obligations. The company expects to initiate a Phase 1 trial of the Nectin-4 x CD3 TCE bispecific in solid tumors in Q3 2026.
1. License Amendment Terms
Context Therapeutics agreed to amend its exclusive license for CT-202 by making a $4.5 million upfront payment and a $2.0 million second payment due by August 1, 2026. In return, the company has eliminated all future milestone and royalty obligations owed for CT-202 development and commercialization.
2. Strategic Impact
By securing full economic rights to its Nectin-4 x CD3 T cell engager, Context gains greater control over future development decisions and potential revenue streams. The buyout underscores the program’s importance within the pipeline and enhances the upside from any clinical or commercial successes.
3. CT-202 Clinical Timeline
Context plans to initiate the Phase 1 clinical trial of CT-202 targeting solid tumors in the third quarter of 2026. The trial will assess safety, tolerability and preliminary efficacy of the pH-dependent bispecific antibody designed to preferentially activate within the tumor microenvironment.
